Journey Medical Corporation
NASDAQ:DERM · NASDAQ Capital Market
+$0.06 today
Vol 0.40M · Avg 0.28M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:DERM · Revenue to Net Income
Key Ratios
Analysis
$64.7M of revenue converted into -$9.6M of net income for the selected period. Gross margin is 60.2% and net margin is -15.0%, showing how much revenue survives after costs and taxes. EPS is $-0.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.9M +10.2% | $56.1M -29.1% | $79.2M +7.5% | $73.7M +16.7% | $63.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $25.2M +20.6% | $20.9M -21.7% | $26.7M -13.4% | $30.8M -4.1% | $32.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $36.7M +4.0% | $35.3M -32.9% | $52.5M +22.4% | $42.9M +38.1% | $31.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 59.3% -3.5pp | 62.8% -3.5pp | 66.3% +8.1pp | 58.2% +9.0pp | 49.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $480.0K -95.1% | $9.9M +30.7% | $7.5M -31.1% | $10.9M -33.9% | $16.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $44.4M +10.4% | $40.2M -8.4% | $43.9M -26.2% | $59.5M +49.3% | $39.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $44.8M -8.3% | $48.9M -10.4% | $54.6M -22.5% | $70.4M +6.8% | $65.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.3M +23.6% | $3.5M -8.8% | $3.9M -11.7% | $4.4M +70.5% | $2.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$3.3M +60.4% | -$8.4M -537.1% | $1.9M +108.3% | -$23.2M +29.3% | -$32.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -5.4% +9.6pp | -15.0% -17.4pp | 2.4% +33.9pp | -31.5% +20.4pp | -51.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$8.2M +40.3% | -$13.7M -559.8% | -$2.1M +92.5% | -$27.5M +21.1% | -$34.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -13.2% +11.2pp | -24.4% -21.7pp | -2.6% +34.7pp | -37.4% +17.9pp | -55.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $589.0K -22.2% | $757.0K +135.1% | $322.0K +436.7% | $60.0K +2900.0% | $2.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.7M +37.0% | $2.7M +59.0% | $1.7M -15.9% | $2.0M -71.3% | $7.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.2M -242.5% | -$934.0K +40.1% | -$1.6M +23.9% | -$2.0M +72.6% | -$7.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$11.4M +22.2% | -$14.6M -302.3% | -$3.6M +87.7% | -$29.6M +30.2% | -$42.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -18.4% +7.6pp | -26.0% -21.4pp | -4.6% +35.5pp | -40.1% +27.0pp | -67.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $60.0K -1.6% | $61.0K -72.4% | $221.0K +250.8% | $63.0K -96.1% | $1.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$11.4M +22.1% | -$14.7M -280.8% | -$3.9M +87.0% | -$29.6M +32.7% | -$44.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -18.5% +7.7pp | -26.1% -21.3pp | -4.9% +35.4pp | -40.2% +29.5pp | -69.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +34.7% | -$1 -242.9% | -$0 +87.6% | -$2 +33.5% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +34.7% | -$1 -242.9% | -$0 +87.6% | -$2 +33.5% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $24.5M +19.9% | $20.4M +12.1% | $18.2M +4.0% | $17.5M +1.2% | $17.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $24.5M +19.9% | $20.4M +12.1% | $18.2M +4.0% | $17.5M +1.2% | $17.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
OraSure Technologies, Inc.
NASDAQ:OSUR
$299.38M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$280.59M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$256.08M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$234.68M
Inventiva S.A.
NASDAQ:IVA
$184.28M
MediWound Ltd.
NASDAQ:MDWD
$153.38M
Organigram Global Inc.
NASDAQ:OGI
$136.55M
Solana Company
NASDAQ:HSDT
$93.42M
Nyxoah S.A.
NASDAQ:NYXH
$61.39M
China SXT Pharmaceuticals, Inc.
SXTC
$1.72M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DERM generate?
Journey Medical Corporation (DERM) reported $61.86M of revenue in fiscal 2025.
Is DERM profitable?
Journey Medical Corporation (DERM) reported -$11,431,000.00 of net income, with a net margin of -18.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.